BRISBANE, Calif.--(BUSINESS WIRE)--Dec. 6, 2005--Tercica, Inc. (Nasdaq:TRCA) today announced the filing, in the United States District Court for the Northern District of California, of a complaint against Insmed Incorporated (Nasdaq:INSM) for false and misleading promotional statements and unfair business practices made in anticipation of Insmed receiving U.S. Food and Drug Administration (FDA) approval for a product to compete with Increlex(TM) (Tercica’s FDA-approved product for the long-term treatment of severe primary IGF-1 deficiency).
